Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 10:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,414 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Patient activation Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

A Multi-Level Strategy for De-implementing Mammography Overuse Among Older Women

NCT07511621
View directory record Official record
Conditions
Mammography, Medical Overuse, Evidence-based Practice, Older Adults
Interventions
Enhanced Usual Care, Multilevel De-Implementation Strategy
Other · Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 3, 2026, 10:26 AM EDT
Not listed No phase listed Observational

Evaluation of the Optimal Transition Program

NCT04263233
View directory record Official record
Conditions
ESRD, Hemodialysis
Interventions
Analysis using descriptive statistics of patient clinical outcomes., Surveys with participants using validated survey tools., Evaluation of the program process including time, costs, referral rates, admission to the program and length of stay.
Other
Lead sponsor
Satellite Healthcare
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Oakland, California • Sacramento, California • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Sep 3, 2026, 10:26 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy

NCT03965689
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Squamous Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Lung Non-Squamous Non-Small Cell Carcinoma
Interventions
Carboplatin, Paclitaxel, Pevonedistat
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
10
States / cities
Los Angeles, California • Newport Beach, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 3, 2026, 10:26 AM EDT
Completed Not applicable Interventional Results available

Transdiagnostic Psychotherapy for Veterans With Mood and Anxiety Disorders

NCT01947647
View directory record Official record
Conditions
Major Depressive Disorder, Persistent Depressive Disorder, Posttraumatic Stress Disorder, Panic Disorder, Social Phobia, Specific Phobia, Generalized Anxiety Disorder, Obsessive Compulsive Disorder
Interventions
Transdiagnostic Behavior Therapy, Behavioral Activation Therapy
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 3, 2026, 10:26 AM EDT
Withdrawn Phase 3 Interventional

Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma

NCT02427893
View directory record Official record
Conditions
Melanoma
Interventions
Cobimetinib, Vemurafenib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 14, 2016 · Synced Sep 3, 2026, 10:26 AM EDT
Completed Phase 3 Interventional Results available

RegoNivo vs Standard of Care Chemotherapy in AGOC

NCT04879368
View directory record Official record
Conditions
Gastro-Oesophageal Cancer
Interventions
Regorafenib, Nivolumab, Docetaxel, Paclitaxel, Irinotecan, Trifluridine/Tipracil
Drug · Biological
Lead sponsor
Australasian Gastro-Intestinal Trials Group
Network
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Scottsdale, Arizona • Los Angeles, California • Sioux City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 3, 2026, 10:26 AM EDT
Completed Not applicable Interventional

Implementation Science Approach to Enhancing Depression Treatment in Collaborative Depression Care Settings ( DepCare )

NCT05085886
View directory record Official record
Conditions
Depressive Symptoms
Interventions
DepCare, Enhanced Usual Care
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Sep 3, 2026, 10:26 AM EDT
Completed Not applicable Interventional Results available

FREEOAB Study for Overactive Bladder

NCT04547920
View directory record Official record
Conditions
Overactive Bladder, Urinary Frequency, Urinary Incontinence, Urge, Urinary Urgency
Interventions
Wearable Bladder Modulation System
Device
Lead sponsor
Avation Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
9
States / cities
Stanford, California • Denver, Colorado • Englewood, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Sep 3, 2026, 10:26 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Resistance Training and Testosterone After Spinal Cord Injury

NCT01652040
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Resistance Training and Testosterone Patches, Testosterone Patches
Device · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 50 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Sep 3, 2026, 10:26 AM EDT
Completed Phase 1 Interventional

DAY101 In Gliomas and Other Tumors

NCT03429803
View directory record Official record
Conditions
Low-grade Glioma
Interventions
DAY101
Drug
Lead sponsor
Karen D. Wright, MD
Other
Eligibility
1 Year to 25 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 3, 2026, 10:26 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor

NCT04800627
View directory record Official record
Conditions
Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Pembrolizumab, Pevonedistat
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2022 · Synced Sep 3, 2026, 10:26 AM EDT
Recruiting Phase 2 Interventional

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

NCT06295159
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma, Melanoma
Interventions
Nivolumab, Nivolumab + Relatlimab, Ipilimumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 3, 2026, 10:26 AM EDT
Active, not recruiting No phase listed Observational

An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment

NCT06883240
View directory record Official record
Conditions
Von Willebrand Disease, Type 3
Interventions
Von Willebrand Factor Concentrates, Von Willebrand Factor Concentrates and Factor VIII Concentrates, Factor VIII Concentrates, Recombinant Activated Factor VII, Activated Prothrombin Complex Concentrate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Sacramento, California • Minneapolis, Minnesota • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 3, 2026, 10:26 AM EDT
Recruiting No phase listed Observational

A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy

NCT05630989
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
combination therapy with no MEKi, combination therapy with MEKi-HCQ, combination therapy with MEKi-EGFRi, combination therapy with MEKi.
Other · Drug
Lead sponsor
Mandana Kamgar, MD
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 3, 2026, 10:26 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

NCT03112590
View directory record Official record
Conditions
Breast Cancer, Breast Cancer, Male, Breast Cancer Female, HER2-positive Breast Cancer
Interventions
Interferon-gamma (IFN-γ), Paclitaxel, Trastuzumab, Pertuzumab, Post Therapy Surgery
Biological · Drug · Other + 1 more
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Sep 3, 2026, 10:26 AM EDT
Not listed No phase listed Observational

Pharmacogenomic Biomarker Study for Recombinant Human Activated Protein C Treatment in Severe Sepsis

NCT01486524
View directory record Official record
Conditions
Severe Sepsis, Septic Shock
Interventions
Not listed
Lead sponsor
Sirius Genomics Inc.
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2011 · Synced Sep 3, 2026, 10:26 AM EDT
Completed Phase 1 Interventional

AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer

NCT04973683
View directory record Official record
Conditions
Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma
Interventions
AL101, Therapeutic Conventional Surgery
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 3, 2026, 10:26 AM EDT
Completed Not applicable Interventional

Tablet-Aided BehavioraL Intervention EffecT on Self-management Skills

NCT02128854
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Noninsulin Dependent, Diabetes Mellitus, Type II
Interventions
Tablets Intervention
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
45 Years to 100 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 3, 2026, 10:26 AM EDT
Completed Phase 1 Interventional Results available

Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions

NCT01241903
View directory record Official record
Conditions
Acute Coronary Syndrome, Angioplasty, Transluminal, Percutaneous Coronary, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Blood Platelets
Interventions
rosuvastatin, placebo
Drug
Lead sponsor
Susan Smyth
Other
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 3, 2026, 10:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Real-time Biofeedback With 7-Tesla MRI for Treatment of Depression

NCT04138680
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Active Biofeedback, Sham Biofeedback
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Sep 3, 2026, 10:26 AM EDT
Withdrawn Early Phase 1 Interventional

Patient Acuity Rating: a Tool to Prevent In-Hospital Cardiac Arrest

NCT01082991
View directory record Official record
Conditions
Heart Arrest
Interventions
Preemptive Rapid Response Team intervention
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Sep 3, 2026, 10:26 AM EDT
Completed No phase listed Observational

(PROSPECTOR) Screening Study Evaluating the Prevalence of the KIT D816V Mutation in Patients With Systemic Mast Cell Activation

NCT04811365
View directory record Official record
Conditions
Systemic Mast Cell Activation, KIT D816V Mutation
Interventions
Screening
Other
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Birmingham, Alabama • San Diego, California • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Sep 3, 2026, 10:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Fatty Acid Regulation of Platelet Function in Diabetes

NCT02373332
View directory record Official record
Conditions
Thrombosis, Type 2 Diabetes Mellitus
Interventions
omega-3 and -6 fatty acids and their 12-LOX oxylipins
Other
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
2
States / cities
Ann Arbor, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Sep 3, 2026, 10:26 AM EDT
Completed No phase listed Observational

Platelet Function on Abacavir and Tenofovir

NCT03081572
View directory record Official record
Conditions
Cardiovascular Diseases, Platelet Aggregation, Spontaneous, HIV/AIDS
Interventions
Platelet aggregation
Diagnostic Test
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Sep 3, 2026, 10:26 AM EDT